Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension

Published: Sep 27, 2011

CAMBRIDGE, Mass., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Tarix Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted TXA127, the Company's lead peptide drug candidate, orphan drug status for the treatment of pulmonary arterial hypertension (PAH). Emerging science has demonstrated that the naturally occurring peptide angiotensin (1-7), the pharmaceutical ingredient in TXA127, exhibits a protective effect in animal models of PAH, suggesting a potentially beneficial role for TXA127 against this disease.

Back to news